financetom
Business
financetom
/
Business
/
Revenue decline could be closer to 10% in FY21: Cyient
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Revenue decline could be closer to 10% in FY21: Cyient
Jan 28, 2021 2:38 AM

Karthikeyan Natarajan, President & COO of Cyient, on Thursday said that the revenue decline for FY21 for the company could be close to 10 percent.

“We continue to hold the view that we would be closer to the 10 percent de-growth as compared to what we guided in the past,” he said in an interview with CNBC-TV18.

He said that the company has been making steady progress in its financials after the dip in Q1.

“We have been making steady progress after we saw a dip in Q1. We have definitely seen a margin increase in Q2 and we continue to make progress even in Q3 both in terms of revenue growth as well as margin expansion,” he said.

Natarajan said that they had brought in operational efficiencies via offshoring, higher utilisation and employee pyramid. He expects 2021 to be better than 2020.

“We have been able to bring in a lot of operational efficiency in the form of offshoring, utilisation, trying to improve our pyramid structure, and also able to help through automation which has been one of the initiatives we started off 6 months ago. We are trying to work with many of our customers to make sure that we are able to provide the right value at the right price. We are making steady progress on the digital transformation; we expect a lot more to happen on the digital area as we move into 2021. We are hopeful that 2021 will be lot better than 2020,” he said.

According to Natarajan, softness in the aerospace and defence business contributed to the revenue decline over the last few quarters. He further added that the medical and healthcare vertical grew 40 percent year-on-year (YoY) and that the company had added two large healthcare R&D spenders as clients in the last 6 months.

As he said, the order intake in Q3 was a sign of pent-up demand. Cyient closed five large deals worth $106 million in Q3, he added.

Watch video for more.

(Edited by : Niral Sharma)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Oklo Stock Surges To New All-Time Highs Monday: What's Driving The Action?
Oklo Stock Surges To New All-Time Highs Monday: What's Driving The Action?
Oct 13, 2025
Shares of Oklo Inc ( OKLO ) soared to a new all-time high Monday morning, continuing a powerful rally fueled by optimistic analyst coverage and increasing demand for clean energy. Here’s what investors need to know. What To Know: The advanced nuclear energy company has gained 1,600% over the past year, driven by the growing need for reliable power for...
American Battery Technology (ABAT) Stock Is Rising: What's Going On?
American Battery Technology (ABAT) Stock Is Rising: What's Going On?
Oct 13, 2025
Shares of American Battery Technology Co ( ABAT ) are trading higher Monday morning after the company announced it has completed a critical step in developing its Tonopah Flats Lithium Project in Nevada. Here’s what investors need to know. What To Know: American Battery ( ABAT ) has finished all required National Environmental Policy Act (NEPA) baseline studies and submitted...
Airbus sees supply progress, Spirit deal to close in fourth quarter
Airbus sees supply progress, Spirit deal to close in fourth quarter
Oct 13, 2025
PARIS (Reuters) -Airbus has seen a marked improvement in confidence and performance from its suppliers, all of whom are ready to support the company's target of increasing deliveries by 7% to some 820 jets this year, a senior company official said on Monday. The European planemaker is also on its way towards a longer-term goal of increasing underlying output of...
AbbVie Gains FDA Approval for Expanded Rinvoq Use in IBD Patients
AbbVie Gains FDA Approval for Expanded Rinvoq Use in IBD Patients
Oct 13, 2025
11:24 AM EDT, 10/13/2025 (MT Newswires) -- AbbVie ( ABBV ) said Monday that the US Food and Drug Administration approved an updated Rinvoq indication for adults with moderately to severely active ulcerative colitis and Crohn's disease. The updated label permits Rinvoq use before tumor necrosis factor blockers for patients unsuited to TNF inhibitors who have tried at least one...
Copyright 2023-2026 - www.financetom.com All Rights Reserved